Peginterferon alpha-2a (PegIFN alpha-2a)

DRUG2 trials

Sponsors

Janssen R&D Ireland

Conditions

Hepatitis C

Phase 3

An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

CompletedNCT01281839

Janssen R&D IrelandHepatitis C

Start: 2011-02-28End: 2013-02-28Updated: 2014-04-23

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

CompletedNCT01289782

Janssen R&D IrelandHepatitis C

Start: 2011-02-28End: 2013-01-31Updated: 2014-06-04

Related Papers

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.

2018-01-305 citations

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.

2017-06-021 citations

Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial.

2016-05-262 citations

Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin

Open Forum Infectious Diseases2016-01-015 citations

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

2014-06-04328 citations

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.

2014-03-03183 citations